TY - JOUR
T1 - Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer.
AU - Chen, Ming Huang
AU - Chang, Peter Mu Hsin
AU - Chen, Po Min
AU - Tzeng, Cheng Hwai
AU - Chu, Pen Yuan
AU - Chang, Shyue Yih
AU - Yang, Muh Hwa
N1 - Funding Information:
Acknowledgments This work was partially supported by Taiwan Clinical Oncology Research Foundation.
PY - 2009/12
Y1 - 2009/12
N2 - BACKGROUND: The purpose of this retrospective study was to test whether the pretreatment hematologic profile can predict the prognosis of patients with head and neck cancer. METHODS: Medical records from 278 patients with head and neck cancer were reviewed, and 270 cases were evaluable. Clinical data including age, gender, stage, pretreatment hematologic profile (including white blood cell, platelet, and differential counts, and hemoglobin level) were recorded. Statistical analyses were performed to determine the prognostic effect of these hematologic indicators, as well as clinical variables. The association between the hematologic indicators and clinical factors was also analyzed. RESULTS: Pretreatment monocytes >1,000 cells/microl (P = 0.028), hemoglobin <11.0 g/dl (P = 0.022), and platelet count >400 x 10(3) cells/microl (P = 0.017) were identified as independent prognostic factors in addition to the nodal status and metastasis. A significant correlation between T-stage/monocyte or platelet count and metastasis/platelet count were shown. Monocytosis, anemia, and thrombocytosis were demonstrated to have a cumulative effect on the prognosis of head and neck cancer patients (normal vs. abnormality in one lineage, P = 0.001; abnormality in one vs. more than one lineage, P = 0.005). CONCLUSIONS: A pretreatment hematologic profile can be considered as a useful prognostic marker in patients with head and neck cancer.
AB - BACKGROUND: The purpose of this retrospective study was to test whether the pretreatment hematologic profile can predict the prognosis of patients with head and neck cancer. METHODS: Medical records from 278 patients with head and neck cancer were reviewed, and 270 cases were evaluable. Clinical data including age, gender, stage, pretreatment hematologic profile (including white blood cell, platelet, and differential counts, and hemoglobin level) were recorded. Statistical analyses were performed to determine the prognostic effect of these hematologic indicators, as well as clinical variables. The association between the hematologic indicators and clinical factors was also analyzed. RESULTS: Pretreatment monocytes >1,000 cells/microl (P = 0.028), hemoglobin <11.0 g/dl (P = 0.022), and platelet count >400 x 10(3) cells/microl (P = 0.017) were identified as independent prognostic factors in addition to the nodal status and metastasis. A significant correlation between T-stage/monocyte or platelet count and metastasis/platelet count were shown. Monocytosis, anemia, and thrombocytosis were demonstrated to have a cumulative effect on the prognosis of head and neck cancer patients (normal vs. abnormality in one lineage, P = 0.001; abnormality in one vs. more than one lineage, P = 0.005). CONCLUSIONS: A pretreatment hematologic profile can be considered as a useful prognostic marker in patients with head and neck cancer.
UR - http://www.scopus.com/inward/record.url?scp=70349771103&partnerID=8YFLogxK
U2 - 10.1007/s00432-009-0625-1
DO - 10.1007/s00432-009-0625-1
M3 - Article
C2 - 19551407
AN - SCOPUS:70349771103
SN - 0171-5216
VL - 135
SP - 1783
EP - 1790
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 12
ER -